Comparative Efficacies of Linezolid vs. Tedizolid in an Experimental Murine Model of Vancomycin-Resistant Enterococcal (VRE) Bacteremia

Wessam Abdelhady; Nagendra N. Mishra; Nagendra N. Mishra

doi:10.3389/fmed.2019.00031

Frontiers in Medicine (Feb 2019)

Comparative Efficacies of Linezolid vs. Tedizolid in an Experimental Murine Model of Vancomycin-Resistant Enterococcal (VRE) Bacteremia

Wessam Abdelhady,
Nagendra N. Mishra,
Nagendra N. Mishra

Affiliations

Wessam Abdelhady: Division of Infectious Diseases, Los Angeles Biomedical Research Institute at UCLA Medical Center, Torrance, CA, United States
Nagendra N. Mishra: Division of Infectious Diseases, Los Angeles Biomedical Research Institute at UCLA Medical Center, Torrance, CA, United States
Nagendra N. Mishra: David Geffen School of Medicine at UCLA, Los Angeles, CA, United States

DOI: https://doi.org/10.3389/fmed.2019.00031
Journal volume & issue: Vol. 6

Abstract

Read online

Tedizolid (TZD) is an oxazolidinone derivative which demonstrates bacteriostatic activity through inhibition of protein synthesis. We compared the efficacies of TZD and an earlier-generation oxazolidinone, linezolid (LZD), in an experimental murine model of bacteremia caused by two VRE strains (one each E. faecium and E. faecalis). LZD exhibited significantly better efficacy in terms of reduced VRE blood and target tissue densities than TZD in this model.

Published in Frontiers in Medicine

ISSN: 2296-858X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Medicine (General)
Website: http://www.frontiersin.org/journals/medicine

About the journal

Abstract

Keywords